ClinicalTrials.gg
WithdrawnNCT06901349Updated Sep 24, 2025

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

A Phase 2 interventional study of Bimagrumab and Tirzepatide in Obesity and Overweight, sponsored by Eli Lilly and Company. Withdrawn at 50 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-09-24.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Study terminated for strategic business reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
103rd of 104
0 · median 69
Started
2025
with 33 others
Phase 2
22 of 104
14 open now
Registered
48th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 103rd largest by enrollment, is one of 34 that started in 2025, is one of 22 in phase 2, and was the 48th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Type 2 Diabetes
  • Muscle
  • Lean
  • Fat
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have type 2 diabetes
  • Have a of ≥27 kilograms per square meter (kg/m2)
  • Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)

Exclusion criteria

Exclusion Criteria:

  • Have a prior or planned surgical treatment for obesity,
  • Have type 1 diabetes, latent diabetes, or history of ketoacidosis or hyperosmolar state or coma
  • Have poorly controlled hypertension
  • Have any of the following cardiovascular conditions within 3 months prior to screening:

    • acute myocardial infarction
    • cerebrovascular accident (stroke)
    • unstable angina, or
    • hospitalization due to congestive heart failure
  • Have a history of (NYHA) Functional Classification III or IV congestive heart failure
  • Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
  • Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
  • Have renal impairment
  • Have a history of symptomatic gallbladder disease within the past 2 years
  • Have signs and symptoms of any liver disease
  • Have a disease or condition known to cause gastrointestinal malabsorption or a known gastric emptying abnormality
  • Have a history of acute or chronic pancreatitis
  • Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Bimagrumab Dose 1 + Tirzepatide Placebo

    Participants will receive bimagrumab subcutaneously (SC) and tirzepatide placebo SC

    Drug: Bimagrumab · Drug: Tirzepatide Placebo

  • Experimental
    Bimagrumab Dose 2 + Tirzepatide Placebo

    Participants will receive bimagrumab SC and tirzepatide placebo SC

    Drug: Bimagrumab · Drug: Tirzepatide Placebo

  • Experimental
    Tirzepatide Dose 1 + Bimagrumab Placebo

    Participants will receive tirzepatide SC and bimagrumab placebo SC

    Drug: Tirzepatide · Drug: Bimagrumab Placebo

  • Experimental
    Tirzepatide Dose 2 + Bimagrumab Placebo

    Participants will receive tirzepatide SC and bimagrumab placebo SC

    Drug: Tirzepatide · Drug: Bimagrumab Placebo

  • Experimental
    Bimagrumab Dose 2 + Tirzepatide Dose 1

    Participants will receive bimagrumab SC and tirzepatide SC

    Drug: Bimagrumab · Drug: Tirzepatide

  • Experimental
    Bimagrumab Dose 1 + Tirzepatide Dose 1

    Participants will receive bimagrumab SC and tirzepatide SC

    Drug: Bimagrumab · Drug: Tirzepatide

  • Experimental
    Bimagrumab Dose 2 + Tirzepatide Dose 2

    Participants will receive bimagrumab SC and tirzepatide SC

    Drug: Bimagrumab · Drug: Tirzepatide

  • Experimental
    Bimagrumab Dose 1 + Tirzepatide Dose 2

    Participants will receive bimagrumab SC and tirzepatide SC

    Drug: Bimagrumab · Drug: Tirzepatide

  • Placebo comparator
    Bimagrumab Placebo + Tirzepatide Placebo

    Participants will receive bimagrumab placebo SC and tirzepatide placebo SC

    Drug: Bimagrumab Placebo · Drug: Tirzepatide Placebo

Interventions

  • Administered SC

    Also known as: LY3985863

  • Administered SC

    Also known as: LY3298176

  • DrugBimagrumab Placebo

    Administered SC

  • DrugTirzepatide Placebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 36

Secondary outcomes

  1. Percent Change from Baseline in Total Body Fat Mass by Dual-Energy X-Ray Absorptiometry (DXA)

    Time frame: Baseline, Week 36

  2. Change from Baseline in Hemoglobin A1c (HbA1c)

    Time frame: Baseline, Week 36

  3. Percentage of Participants Achieving ≥5% Body Weight Reduction

    Time frame: Baseline, Week 36

  4. Percentage of Participants Achieving ≥10% Body Weight Reduction

    Time frame: Baseline, Week 36

  5. Percentage of Participants Achieving ≥15% Body Weight Reduction

    Time frame: Baseline, Week 36

  6. Change from Baseline in Waist Circumference

    Time frame: Baseline, Week 36

  7. Change from Baseline in Body Mass Index (BMI)

    Time frame: Baseline, Week 36

  8. Change from Baseline in Waist-to-Height Ratio (WHtR)

    Time frame: Baseline, Week 36

  9. Percent Change from Baseline in Visceral Adipose Tissue (VAT) by Magnetic Resonance Imaging (MRI)

    Time frame: Baseline, Week 36

  10. Change from Baseline in Liver Fat by MRI

    Time frame: Baseline, Week 36

  11. Percent Change from Baseline in High-Sensitivity C-Reactive Protein (hsCRP)

    Time frame: Baseline, Week 36

  12. Percent Change from Baseline in Total Cholesterol

    Time frame: Baseline, Week 36

  13. Percent Change from Baseline in Triglycerides (TG)

    Time frame: Baseline, Week 36

  14. Change from Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 36

  15. Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC-ss) of Bimagrumab

    Time frame: Predose through Week 52

07

Study locations

50 sites
  • Yuma Clinical Trials
    Yuma, Arizona 85364, United States
  • Orange County Research Center
    Lake Forest, California 92630, United States
  • Healthy Brain Clinic
    Long Beach, California 90804, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Excel Medical Clinical Trials
    Boca Raton, Florida 33434, United States
  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
    Jacksonville, Florida 32256, United States
  • L&C Professional Medical Research Institute
    Miami, Florida 33144, United States
  • Global Health Research Center, Inc.
    Miami Lakes, Florida 33016, United States
  • Charter Research - Winter Park
    Orlando, Florida 32803, United States
  • Charter Research - Lady Lake
    The Villages, Florida 32162, United States
  • Balanced Life Health Care Solutions/SKYCRNG
    Lawrenceville, Georgia 30046, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Bingham Memorial Hospital
    Blackfoot, Idaho 83221, United States
  • Family First Medical Center
    Idaho Falls, Idaho 83404, United States
  • Deaconess Clinic- Gateway
    Newburgh, Indiana 47630, United States
  • Kur Research - Columbia Medical
    Columbia, Maryland 21045, United States
  • Great Lakes Research Group, Inc.
    Bay City, Michigan 48706, United States
  • University of North Carolina Medical Center
    Chapel Hill, North Carolina 27514, United States
  • Remington-Davis, Inc
    Columbus, Ohio 43215, United States
  • Central States Research
    Tulsa, Oklahoma 74136, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Activian Clinical Research
    Kingwood, Texas 77339, United States
  • Northwest Clinical Research Center
    Bellevue, Washington 98007, United States
  • CIPREC
    Buenos Aires, Buenos Aires F.D. C1119ACN, Argentina
  • Centro Médico Viamonte
    Buenos Aires, Buenos Aires F.D. C1120AAC, Argentina
  • Consultorio de Investigación Clínica EMO SRL
    Buenos Aires, Buenos Aires F.D. C1405BUB, Argentina
  • CIPREC
    Buenos Aires, C1061AAS, Argentina
  • Richmond Clinical Trials
    Richmond, British Columbia V6V 2L1, Canada
  • Centricity Research Brampton Endocrinology
    Brampton, Ontario L6S 0C6, Canada
  • Premier Clinical Trial Network
    Hamilton, Ontario L8L 5G4, Canada
  • Your Research Network
    Niagara Falls, Ontario L2H 1H5, Canada
  • Centricity Research Pointe-Claire Multispecialty
    Pointe-Claire, Quebec H9R 4S3, Canada
  • Diex Recherche Trois-Rivieres
    Trois-Rivières, Quebec G9A 4P3, Canada
  • Diex Recherche Quebec
    Québec, G1V 4T3, Canada
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang Shi, Henan 471003, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • The First Affiliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Shanghai Sixth People's Hospital
    Shanghai, Shanghai Municipality, China
  • Tokuyama Clinic
    Mihama-ku,Chiba City, Chiba 261-0004, Japan
  • Hayashi Diabetes Internal Medicine Clinic
    Chigasaki, Kanagawa 253-0044, Japan
  • Shonan Takai Clinic
    Kamakura, Kanagawa 247-0055, Japan
  • Takai Internal Medicine Clinic
    Kamakura-shi, Kanagawa 247-0056, Japan
  • Medical Corporation Heishinkai OCROM Clinic
    Suita-shi, Osaka 565-0853, Japan
  • The Institute of Medical Science, Asahi Life Foundation
    Chuo-ku, Tokyo 103-0002, Japan
  • Tokyo-Eki Center-building Clinic
    Chuo-ku, Tokyo 103-0027, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2025 to primary completion in Jun 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2025
First posted
Mar 28, 2025
StartActual
May 23, 2025
Primary completionActual
Jun 10, 2025
CompletionActual
Jun 10, 2025
Last update
Sep 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06901349
Responsible party
Sponsor
First posted
Mar 28, 2025
Start date
May 23, 2025
Primary completion
Jun 10, 2025
Completion
Jun 10, 2025
Last update
Sep 24, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bimagrumab · Tirzepatide

Start the discussion